{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:16:47Z","timestamp":1789881407557,"version":"4.0.1"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jaut.2016.06.010","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T05:52:33Z","timestamp":1467179553000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Immunomodulators in SLE: Clinical evidence and immunologic actions"],"prefix":"10.1016","volume":"74","author":[{"given":"L.","family":"Durcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrrheum.2015.174","article-title":"Towards new avenues in the management of lupus glomerulonephritis","volume":"12","author":"Mok","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"20","key":"10.1016\/j.jaut.2016.06.010_bib2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1001\/archinte.160.20.3136","article-title":"Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995","volume":"160","author":"Ward","year":"2000","journal-title":"Arch. Intern Med."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0889-8529(18)30275-5","article-title":"Control of adrenal androgen secretion","volume":"20","author":"Parker","year":"1991","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-2004-861553","article-title":"Adrenal androgens and the immune system","volume":"22","author":"Chen","year":"2004","journal-title":"Semin. Reprod. Med."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2016.06.010_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530600569877","article-title":"The biological actions of dehydroepiandrosterone involves multiple receptors","volume":"38","author":"Webb","year":"2006","journal-title":"Drug Metab. Rev."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0049-0172(98)80013-9","article-title":"Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus","volume":"27","author":"Derksen","year":"1998","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1043-2760(02)00609-4","article-title":"Dissecting human adrenal androgen production","volume":"13","author":"Rainey","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.mce.2013.03.009","article-title":"Genome-wide association studies on serum sex steroid levels","volume":"382","author":"Vandenput","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib9","first-page":"2960","article-title":"Dehydroepiandrosterone (DHEA)\u2013a precursor steroid or an active hormone in human physiology","volume":"8","author":"Traish","year":"2011","journal-title":"J.\u00a0Sex. Med."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib10","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1210\/en.2005-0368","article-title":"Direct agonist\/antagonist functions of dehydroepiandrosterone","volume":"146","author":"Chen","year":"2005","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/dmd.30.5.570","article-title":"Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor","volume":"30","author":"Ripp","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib12","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1210\/jc.2005-0915","article-title":"Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging","volume":"90","author":"Hammer","year":"2005","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jaut.2016.06.010_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.1995.tb17369.x","article-title":"DHEA and peripheral androgen and estrogen formation: intracinology","volume":"774","author":"Labrie","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2016.06.010_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jsbmb.2014.06.003","article-title":"DHEA, DHEAS and PCOS","volume":"145","author":"Goodarzi","year":"2015","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib15","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.11105","article-title":"Sex hormones and systemic lupus erythematosus: review and meta-analysis","volume":"48","author":"McMurray","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.1780300301","article-title":"Low plasma androgens in women with systemic lupus erythematosus","volume":"30","author":"Lahita","year":"1987","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2249.1995.tb05541.x","article-title":"Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE)","volume":"99","author":"Suzuki","year":"1995","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0006-3223(96)00043-1","article-title":"Dehydroepiandrosterone (DHEA) treatment of depression","volume":"41","author":"Wolkowitz","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpsychires.2009.07.002","article-title":"Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA","volume":"44","author":"Ritsner","year":"2010","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psyneuen.2006.11.002","article-title":"Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial","volume":"32","author":"Strous","year":"2007","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010054022079","article-title":"Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders","volume":"4","author":"Dillon","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/ard.2003.016576","article-title":"Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus","volume":"63","author":"Chang","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib23","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1172\/JCI111929","article-title":"Prevention of autoantibody formation and prolonged survival in New Zealand black\/New Zealand white F1 mice fed dehydroisoandrosterone","volume":"75","author":"Lucas","year":"1985","journal-title":"J.\u00a0Clin. Invest"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/08916939708994738","article-title":"Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB\/W mice","volume":"26","author":"Norton","year":"1997","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/eje.0.1460365","article-title":"Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor","volume":"146","author":"Straub","year":"2002","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/096120339600500603","article-title":"Serum and urinary interleukin-6 in systemic lupus erythematosus","volume":"5","author":"Peterson","year":"1996","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib27","first-page":"16","article-title":"Urinary levels of IL-6 in patients with active lupus nephritis","volume":"40","author":"Iwano","year":"1993","journal-title":"Clin. Nephrol."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0961203313512882","article-title":"Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus","volume":"23","author":"Ball","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.62.1.37","article-title":"Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE","volume":"62","author":"R\u00f6nnelid","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.1780370906","article-title":"An open study of dehydroepiandrosterone in systemic lupus erythematosus","volume":"37","author":"van Vollenhoven","year":"1994","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1191\/096120399678847588","article-title":"A\u00a0double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus","volume":"8","author":"van Vollenhoven","year":"1999","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib32","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib33","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.10615","article-title":"Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial","volume":"46","author":"Chang","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib34","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/art.20610","article-title":"The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus","volume":"50","author":"Hartkamp","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib35","first-page":"616","article-title":"Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy","volume":"32","author":"Mease","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib36","first-page":"1567","article-title":"Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy","volume":"35","author":"S\u00e1nchez-Guerrero","year":"2008","journal-title":"J.\u00a0Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/08916930500285550","article-title":"Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus","volume":"38","author":"Nordmark","year":"2005","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/art.1780400506","article-title":"The reliability of the systemic lupus international collaborating clinics\/american College of Rheumatology damage index in patients with systemic lupus erythematosus","volume":"40","author":"Gladman","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jn\/134.6.1299","article-title":"The discovery of vitamin D: the contribution of Adolf Windaus","volume":"134","author":"Wolf","year":"2004","journal-title":"J.\u00a0Nutr."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.soard.2016.01.001","article-title":"Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review","volume":"12","author":"Peterson","year":"2016","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6 Suppl","key":"10.1016\/j.jaut.2016.06.010_bib42","doi-asserted-by":"crossref","first-page":"1689S","DOI":"10.1093\/ajcn\/80.6.1689S","article-title":"Overview of general physiologic features and functions of vitamin D","volume":"80","author":"DeLuca","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.jaut.2016.06.010_bib43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3389\/fimmu.2015.00513","article-title":"Immune response modulation by vitamin D: role in systemic lupus erythematosus","volume":"6","author":"Iruretagoyena","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.autrev.2010.06.009","article-title":"Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice","volume":"9","author":"Souberbielle","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.jaut.2016.06.010_bib46","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.SMJ.0000140865.32054.DB","article-title":"Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers","volume":"98","author":"Holick","year":"2005","journal-title":"South Med. J."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1474-4422(10)70086-7","article-title":"Vitamin D and multiple sclerosis","volume":"9","author":"Ascherio","year":"2010","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib48","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.22722","article-title":"Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis","volume":"56","author":"Patel","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02207671","article-title":"Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus","volume":"14","author":"M\u00fcller","year":"1995","journal-title":"Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib50","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/ard.2010.148494","article-title":"Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus","volume":"70","author":"Ritterhouse","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jpeds.2009.02.033","article-title":"Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus","volume":"155","author":"Wright","year":"2009","journal-title":"J.\u00a0Pediatr."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2005.05.009","article-title":"Vitamin D deficiency in systemic lupus erythematosus","volume":"5","author":"Kamen","year":"2006","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib53","first-page":"2535","article-title":"Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia","volume":"28","author":"Huisman","year":"2001","journal-title":"J.\u00a0Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/eci.13.19","article-title":"Vitamin D and systemic lupus erythematosus: an update","volume":"9","author":"Mok","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"21","key":"10.1016\/j.jaut.2016.06.010_bib56","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1306357","article-title":"Vitamin D-binding protein and vitamin D status of black Americans and white Americans","volume":"369","author":"Powe","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib57","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/acr.21776","article-title":"Dietary intake of vitamin D during adolescence and risk of adult-onset systemic lupus erythematosus and rheumatoid arthritis","volume":"64","author":"Hiraki","year":"2012","journal-title":"Arthritis Care Res. Hob."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib58","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.4049\/jimmunol.179.3.1634","article-title":"Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation","volume":"179","author":"Chen","year":"2007","journal-title":"J.\u00a0Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2310\/JIM.0b013e31821b8755","article-title":"Vitamin D and the immune system","volume":"59","author":"Aranow","year":"2011","journal-title":"J.\u00a0Investig. Med."},{"key":"10.1016\/j.jaut.2016.06.010_bib60","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1479-5876-11-176","article-title":"Vitamin D deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study","volume":"11","author":"Ojaimi","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib61","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar2517","article-title":"Myeloid dendritic cells display downregulation of C-type lectin receptors and aberrant lectin uptake in systemic lupus erythematosus","volume":"10","author":"Monrad","year":"2008","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib62","doi-asserted-by":"crossref","first-page":"e9193","DOI":"10.1371\/journal.pone.0009193","article-title":"The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus","volume":"5","author":"Ben-Zvi","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib63","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/art.39108","article-title":"Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus","volume":"67","author":"Aranow","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-008-0676-1","article-title":"Vitamin D deficiency in patients with active systemic lupus erythematosus","volume":"20","author":"Borba","year":"2009","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib65","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/ard.2009.120329","article-title":"Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?","volume":"69","author":"Amital","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1756-185X.2011.01653.x","article-title":"Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids","volume":"15","author":"Yeap","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/rheumatology\/ker352","article-title":"25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus","volume":"51","author":"Reynolds","year":"2012","journal-title":"Rheumatol. Oxf."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib68","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/rheumatology\/ker212","article-title":"Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis","volume":"51","author":"Mok","year":"2012","journal-title":"Rheumatol. Oxf."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib69","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/acr.22291","article-title":"25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort","volume":"66","author":"Lertratanakul","year":"2014","journal-title":"Arthritis Care Res. Hob."},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib70","first-page":"352","article-title":"Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus","volume":"60","author":"Becker","year":"2001","journal-title":"Z\u00a0Rheumatol."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib71","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0961203311405703","article-title":"Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus","volume":"20","author":"Bonakdar","year":"2011","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib72","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/acr.20186","article-title":"Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage","volume":"62","author":"Ruiz-Irastorza","year":"2010","journal-title":"Arthritis Care Res. Hob."},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib73","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1186\/ar4060","article-title":"Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation","volume":"14","author":"Terrier","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib74","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/art.37953","article-title":"Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3899\/jrheum.111594","article-title":"The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial","volume":"40","author":"Abou-Raya","year":"2013","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib76","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/acr.22621","article-title":"Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Lima","year":"2016","journal-title":"Arthritis Care Res. Hob."},{"issue":"4\u20135","key":"10.1016\/j.jaut.2016.06.010_bib77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/0961203314559089","article-title":"A\u00a024-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus","volume":"24","author":"Andreoli","year":"2015","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib78","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.amjcard.2008.06.067","article-title":"Prevalence of hypovitaminosis D in cardiovascular diseases (from the national health and nutrition examination survey 2001 to 2004)","volume":"102","author":"Kim","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.STR.0000195184.24297.c1","article-title":"Reduced vitamin D in acute stroke","volume":"37","author":"Poole","year":"2006","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.atherosclerosis.2008.10.033","article-title":"25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey","volume":"205","author":"Kendrick","year":"2009","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib81","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MAJ.0b013e31823fa7d9","article-title":"Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients","volume":"344","author":"Ravenell","year":"2012","journal-title":"Am. J. Med. Sci."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib82","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A\u00a0randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","year":"1991","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib84","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib85","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib86","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib87","first-page":"1457","article-title":"Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus","volume":"21","author":"Williams","year":"1994","journal-title":"J.\u00a0Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib88","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib89","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","article-title":"Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis","volume":"15","author":"Kasitanon","year":"2006","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib90","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib91","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","article-title":"The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review","volume":"43","author":"Sutton","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib92","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J.\u00a0Am. Acad. Dermatol"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib96","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/art.1780341210","article-title":"Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience","volume":"34","author":"Petri","year":"1991","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib97","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib98","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/acr.22341","article-title":"Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications","volume":"66","author":"Kerr","year":"2014","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib99","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3899\/jrheum.150437","article-title":"Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy","volume":"43","author":"Durcan","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","article-title":"The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas\u2013a randomized trial","volume":"55","author":"Gerstein","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus","volume":"16","author":"James","year":"2007","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.jaut.2016.06.010_bib103","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus","volume":"126","author":"Izmirly","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib105","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J.\u00a0Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib106","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0306-3623(97)00269-3","article-title":"Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis","volume":"30","author":"Bondeson","year":"1998","journal-title":"Gen. Pharmacol."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib107","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clin. (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib108","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib109","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.79.1.175","article-title":"Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells","volume":"79","author":"Ziegler","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6 Pt 2","key":"10.1016\/j.jaut.2016.06.010_bib111","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.lpm.2014.03.007","article-title":"Hydroxychloroquine: a multifaceted treatment in lupus","volume":"43","author":"Costedoat-Chalumeau","year":"2014","journal-title":"Presse Med."},{"issue":"10","key":"10.1016\/j.jaut.2016.06.010_bib112","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib113","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J.\u00a0Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A\u00a0randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group","volume":"324","year":"1991","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib115","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2016.06.010_bib116","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib117","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archdermatol.2011.2558","article-title":"Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study","volume":"148","author":"Franc\u00e8s","year":"2012","journal-title":"Arch. Dermatol"},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib118","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib119","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3899\/jrheum.150379","article-title":"Hydroxychloroquine blood levels in SLE: clarifying dosing controversies and improving adherence","volume":"42","author":"Durcan","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib120","first-page":"1457","article-title":"Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus","volume":"21","author":"Williams","year":"1994","journal-title":"J.\u00a0Rheumatol."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib121","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.autrev.2013.04.006","article-title":"Preventing congenital neonatal heart block in offspring of mothers with anti-SSA\/Ro and SSB\/La antibodies: a review of published literature and registered clinical trials","volume":"12","author":"Gleicher","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.jaut.2016.06.010_bib122","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.4049\/jimmunol.0902248","article-title":"Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block","volume":"184","author":"Clancy","year":"2010","journal-title":"J.\u00a0Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jaut.2016.06.010_bib125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib126","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib127","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib128","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatol. Oxf."},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib129","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib130","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A\u00a0phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2016.06.010_bib131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2016.06.010_bib132","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"9767","key":"10.1016\/j.jaut.2016.06.010_bib133","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaut.2016.06.010_bib134","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib135","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib136","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib137","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","article-title":"Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus","volume":"70","author":"Illei","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2016.06.010_bib138","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203310370051","article-title":"Stem cell transplantation: progress in Asia","volume":"19","author":"Sun","year":"2010","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib139","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/096120339300200304","article-title":"Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus?","volume":"2","author":"Marmont","year":"1993","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaut.2016.06.010_bib140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1191\/0961203304lu525oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"issue":"9231","key":"10.1016\/j.jaut.2016.06.010_bib141","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(00)02627-1","article-title":"Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study","volume":"356","author":"Traynor","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaut.2016.06.010_bib142","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jaut.2016.06.010_bib143","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.0901773","article-title":"Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus","volume":"183","author":"Zhang","year":"2009","journal-title":"J.\u00a0Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2016.06.010_bib144","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/art.38674","article-title":"A\u00a0CD8 T cell\/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus","volume":"66","author":"Wang","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2016.06.010_bib145","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/art.20427","article-title":"Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus","volume":"50","author":"Petri","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib146","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/ard.2009.117036","article-title":"Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial","volume":"69","author":"Hartkamp","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"4\u20135","key":"10.1016\/j.jaut.2016.06.010_bib147","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0961203314559090","article-title":"Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D","volume":"24","author":"Piantoni","year":"2015","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.jaut.2016.06.010_bib148","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:16:27Z","timestamp":1760256987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116300889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":148,"alternative-id":["S0896841116300889"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.06.010","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulators in SLE: Clinical evidence and immunologic actions","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}